Your Logo Here
CYTOCHROME P450 3A AS A MEDIATOR OF CHEMOTHERAPY RESISTANCE IN PATIENTS
WITH SOFT TISSUE SARCOMA
CYTOCHROME P450 3A AS A MEDIATOR OF CHEMOTHERAPY RESISTANCE IN PATIENTS
WITH SOFT TISSUE SARCOMA
DISEASE-FREE SURVIVAL BY IFOSFAMIDE DOSE
Worden, JCO (2005)
ERYTHROMYCIN BREATH TEST
• [14C N-methyl] erythromycin
• CYP3A metabolizes erythromycin, liberating a carbon atom as CO2
• Measures in vivo activity of CYP3A
Dose mean % range % 6 2.4 0.87-4.32 12 2.2 0.43-4.17
CYTOCHROME P450 CYP3A
• Most abundant p450 in liver• Composed of four family members
– 3A4– 3A5– 3A7– 3A43
• Responsible for metabolism of:– Ifosfamide– Vinblastine– Doxorubicin– Etoposide
Normal Liver
Modified after Furlanut and Franceschi (2003) Oncology 65(Suppl 2): 2-6.
ERMBT OVERALL SURVIVAL
P value 0.0992 P value 0.0526
CYP3A QIF AND ERMBT
r2 5.84 x 10-6
QUANTITATIVE IMMUNOFLUORESCENCE (QIF)
• Modification of Indirect IF method• Diminish auto fluorescence with
glycine/PPD• Antibody labeled with Fluor 568• Nuclei labeled with Syto16• Fluorescence analyzed by Mercury
lamp with appropriate filter• Results expressed as F/nuclei
QIF RELIABILITY STUDIES
INTER-ASSAY VARIABILITYINTRA-ASSAY VARIABILITY
BIOLOGICAL STUDIES
• 60/79 patients with FFPE tissue available for study– TMA made
• 19 patients with multiple specimens
• 45/79 patients DNA extracted from FFPE tissue for SNP analysis
QIF CYP3A AND TUMOR HISTOLOGY
TUMOR CYP3A QIF AND SURVIVAL
P value 0.0353*
TUMOR CYP3A QIF AND SURVIVAL
P value 0.0415*
• Decreased ERMBT are suggestive of poorer prognosis.
• Elevated tumor CYP3A protein levels are associated with poor survival.
• No correlations with CYP3A4 or CYP3A5 SNPs.• Prospectively studying patients for CYP3A levels
in new clinical trial.• Examining the role of CYP3A gene induction in
cell lines.
CONCLUSIONS
ACKNOWLEGMENTS
• Larry BAKER• Mark ZALUPSKI• Tom GIORDANO• Sybil BIERMANN• Vernon SONDAK• Rashmi CHUGH• Walther Cancer Research Foundation• Robert Urich Sarcoma Fund• Staff and Patients at University of Michigan
Your Logo Here
CYTOCHROME P450 3A AS A MEDIATOR OF CHEMOTHERAPY RESISTANCE IN PATIENTS
WITH SOFT TISSUE SARCOMA
CYTOCHROME P450 3A AS A MEDIATOR OF CHEMOTHERAPY RESISTANCE IN PATIENTS
WITH SOFT TISSUE SARCOMA